Trial Profile
A Reduced Intensity Conditioning With Clofarabine Antithymocyte Globulin and Total Lymphoid Irradiation Followed by Allogeneic Hematopoietic Stem Cell Transplantation.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Clofarabine (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 22 Nov 2023 Status changed from active, no longer recruiting to completed.
- 02 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 25 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.